Skip to content
10-Q

Quarterly Report

NIKA PHARMACEUTICALS, INC NIKA

0001826466-26-000039

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 1, 2026 1.05B sh
Shares Diluted Q1 2026 · Mar 31, 2026 1.05B sh
Shares Diluted Q1 2026 · Mar 31, 2025 1.03B sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$13.36K
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$12.95K
Short Term Debt Q1 2026 · Mar 31, 2026 $331.62K
Short Term Debt Q1 2026 · Dec 31, 2025 $318.62K
Cash And Equivalents Q1 2026 · Mar 31, 2026 $1.53K
Cash And Equivalents Q1 2026 · Dec 31, 2025 $1.89K
Stockholders Equity Q1 2026 · Mar 31, 2026 −$310.99K
Stockholders Equity Q1 2026 · Dec 31, 2025 −$297.63K
Stockholders Equity Q1 2026 · Mar 31, 2025 −$234.18K
Stockholders Equity restated Q1 2026 · Dec 31, 2024 −$221.23K
Current Liabilities Q1 2026 · Mar 31, 2026 $331.62K
Current Liabilities Q1 2026 · Dec 31, 2025 $318.62K
Total Liabilities Q1 2026 · Mar 31, 2026 $331.62K
Total Liabilities Q1 2026 · Dec 31, 2025 $318.62K
Current Assets Q1 2026 · Mar 31, 2026 $20.64K
Current Assets Q1 2026 · Dec 31, 2025 $21K
Total Assets Q1 2026 · Mar 31, 2026 $20.64K
Total Assets Q1 2026 · Dec 31, 2025 $21K
Eps Diluted Q1 2026 · Mar 31, 2026 $0.00
Eps Diluted Q1 2026 · Mar 31, 2025 $0.00
Eps Basic Q1 2026 · Mar 31, 2026 $0.00
Eps Basic Q1 2026 · Mar 31, 2025 $0.00
Sga Expense Q1 2026 · Mar 31, 2026 $2.64K
Sga Expense Q1 2026 · Mar 31, 2025 $1.8K
Net Income Q1 2026 · Mar 31, 2026 −$13.36K
Net Income Q1 2026 · Mar 31, 2025 −$12.95K
Operating Income Q1 2026 · Mar 31, 2026 −$13.36K
Operating Income Q1 2026 · Mar 31, 2025 −$12.95K